Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study

Journal of Clinical Oncology

Volumn 24, Issue 3, 2006, Pages 500-506

  Matthay, Katherine K ^a   Tan, Jessica C ^a   Villablanca, Judith G ^a   Yanik, Gregory A ^a   Veatch, Janet ^a   Franc, Benjamin ^a   Twomey, Eilish ^a   Horn, Biljana ^a   Reynolds, C Patrick ^a   Groshen, Susan ^a   Seeger, Robert C ^a   Maris, John M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CARBOPLATIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT;

ACIDOSIS; ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ASCITES; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEPATOMEGALY; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INFANT; KIDNEY FAILURE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NEUROBLASTOMA; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; SEIZURE; SEPSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; VEIN OCCLUSION; WEIGHT GAIN; AUTOTRANSPLANTATION; CHILD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; NEUROBLASTOMA; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33644846781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6400     Document Type: Article

References (32)

1. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
2. Seeger RC, Reynolds CP, Gallego R, et al: Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 18:4067-4076, 2000
3. Shulkin BL, Shapiro B, Hutchinson RJ: Iodine-131-metaiodobenzylguanidine and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 33:1735-1740, 1992
4. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
5. Hoefnagel CA, Voute PA, de Kraker J, et al: Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 28:308-314, 1987
6. Hutchinson RJ, Sisson JC, Miser JS, et al: Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 35:237-240, 1991
7. Voute PA, Hoefnagel CA, de Kraker J, et al: Results of treatment with 131 I-metaiodobenzylguanidine 131 I-MIBG in patients with neuroblastoma: Future prospects of zetotherapy. Prog Clin Biol Res 366:439-445, 1991
8. Klingebiel T, Berthold F, Treuner J, et al: Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial. Med Pediatr Oncol 19:84-88, 1991
9. Garaventa A, Bellagamba O, Lo Piccolo MS, et al: 131 I- metaiodobenzylguanidine (131 I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer 81:1378-1384, 1999
10. Matthay KK, DeSantes K, Hasegawa B, et al: Phase I dose escalation of 131 I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:229-236, 1998
11. Matthay KK, Panina C, Huberty J, et al: Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 42: 1713-1721, 2001
12. Matthay KK, Huberty JP, Hattner RS, et al: Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 35:244-247, 1991
13. Goldberg SS, DeSantes K, Huberty JP, et al: Engraftment after myeloablative doses of 131 I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 30:339-346, 1998
14. Dubois SG, Messina J, Maris JM, et al: Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22:2452-2460, 2004
15. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2230-2341, 1993
16. Villablanca JG, Matthay KK, Swift PS, et al: Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous bone marrow transplantation for children with high risk neuroblastoma. Med Pediatr Oncol 33:170, 1999
17. Klingebiel T, Bader P, Bares R, et al: Treatment of neuroblastoma stage 4 with 131 I-metaiodo-benzylguanidine, high-dose chemotherapy and immunotherapy: A pilot study. Eur J Cancer 34: 1398-1402, 1998
18. Corbett R, Pinkerton R, Tait D, et al: [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 35:228-231, 1991
19. Gaze MN, Wheldon TE, O'Donoghue JA, et al: Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 31A:252-256, 1995
20. Yanik GA, Levine JE, Matthay KK, et al: Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142-2149, 2002
21. Edler L: Overview of Phase I Trials, in Crowley J (ed): Handbook of Statistics in Clinical Oncology. New York, NY, Marcel Dekker, 2001, pp 1-35
22. Horn B, Reiss U, Matthay K, et al: Venoocclusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: A high incidence in patients with neuroblastoma. Bone Marrow Transplant 29:409-415, 2002
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
24. Ady N, Zucker JM, Asselain B, et al: A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 31A:256-261, 1995
25. Matthay KK, Edeline V, Lumbroso J, et al: Correlation of early metastatic response by 123-I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486-2491, 2003
26. Barrett A, Nicholls J, Gibson B: Late effects of total body irradiation. Radiother Oncol 9:131-135, 1987
27. Villabianca JG, Reynolds CP, Swift PS, et al: Phase I trial of carboplatin, etoposide, melphalan and local irradiation (CEM-LI) with purged autologous marrow transplantation for children with high risk neuroblastoma. Proc Am Soc Clin Oncol 17: 533a, 1998 (suppl; abstr 2045)
28. Howard JP, Maris JM, Kersun LS, et al: Tumor response and toxicity with multiple infusions of high dose 131 I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44:232-239, 2005
29. Seeger RC, Villablanca JG, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 366:527-533, 1991
30. Hoefnagel CA, Voute PA, De Kraker J, et al: [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med 35:202-206, 1991
31. Philip T, Ladenstein R, Lasset C, et al: 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions - European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 33:2130-2135, 1997
32. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998